Association Between Indoxyl Sulfate and Dialysis Initiation and Cardiac Outcomes in Chronic Kidney Disease Patients

References

• Carney EF. The impact of chronic kidney disease on global health. Nat Rev Nephrol. 2020;16(5):251. doi:10.1038/s41581-020-0268-7
   PubMed Web of Science ®Google Scholar
• System USRD. 2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2020.
   Google Scholar
• Jankowski J, Floege J, Fliser D, Bohm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–1172. doi:10.1161/CIRCULATIONAHA.120.050686
   PubMed Web of Science ®Google Scholar
• Valdivielso JM, Rodriguez-Puyol D, Pascual J, et al. Atherosclerosis in chronic kidney disease: more, less, or just different? Arterioscler Thromb Vasc Biol. 2019;39(10):1938–1966. doi:10.1161/ATVBAHA.119.312705
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305. doi:10.1056/NEJMoa041031
   PubMed Web of Science ®Google Scholar
• Leong SC, Sirich TL. Indoxyl sulfate-review of toxicity and therapeutic strategies. Toxins. 2016;8(12):358. doi:10.3390/toxins8120358
   PubMed Web of Science ®Google Scholar
• Fujii H, Nakai K, Fukagawa M. Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease. Ther Apher Dial. 2011;15(2):125–128. doi:10.1111/j.1744-9987.2010.00883.x
   PubMed Web of Science ®Google Scholar
• Liu S, Wang BH, Kompa AR, Lekawanvijit S, Krum H. Antagonists of organic anion transporters 1 and 3 ameliorate adverse cardiac remodelling induced by uremic toxin indoxyl sulfate. Int J Cardiol. 2012;158(3):457–458. doi:10.1016/j.ijcard.2012.05.022
   PubMed Web of Science ®Google Scholar
• Enomoto A, Takeda M, Tojo A, et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol. 2002;13(7):1711–1720. doi:10.1097/01.ASN.0000022017.96399.B2
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Fuller DS, Komaba H, et al. Serum total indoxyl sulfate and clinical outcomes in hemodialysis patients: results from the Japan Dialysis Outcomes and Practice Patterns Study. Clin Kidney J. 2021;14(4):1236–1243. doi:10.1093/ckj/sfaa121
   PubMed Web of Science ®Google Scholar
• Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(10):1551. doi:10.2215/CJN.03980609
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.e14. doi:10.1016/j.echo.2014.10.003
   PubMed Web of Science ®Google Scholar
• Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314. doi:10.1016/j.echo.2016.01.011
   PubMed Web of Science ®Google Scholar
• Leitman M, Lysyansky P, Sidenko S, et al. Two-dimensional strain-a novel software for real-time quantitative echocardiographic assessment of myocardial function. J Am Soc Echocardiogr. 2004;17(10):1021–1029. doi:10.1016/j.echo.2004.06.019
   PubMed Web of Science ®Google Scholar
• Bansal M, Cho GY, Chan J, Leano R, Haluska BA, Marwick TH. Feasibility and accuracy of different techniques of two-dimensional speckle based strain and validation with harmonic phase magnetic resonance imaging. J Am Soc Echocardiogr. 2008;21(12):1318–1325. doi:10.1016/j.echo.2008.09.021
   PubMed Web of Science ®Google Scholar
• Marwick TH, Leano RL, Brown J, et al. Myocardial strain measurement with 2-dimensional speckle-tracking echocardiography: definition of normal range. JACC Cardiovasc Imaging. 2009;2(1):80–84. doi:10.1016/j.jcmg.2007.12.007
   PubMed Web of Science ®Google Scholar
• Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126(24):2890–2909. doi:10.1161/CIR.0b013e318276fbcb
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamamoto T, Tsuda S, Maruyama M, Shirai K. The background of calculating CAVI: lesson from the discrepancy between cavi and cavi0. Vasc Health Risk Manag. 2020;16:193–201. doi:10.2147/VHRM.S223330
   PubMed Web of Science ®Google Scholar
• Watanabe K, Tominari T, Hirata M, et al. Indoxyl sulfate, a uremic toxin in chronic kidney disease, suppresses both bone formation and bone resorption. FEBS Open Bio. 2017;7(8):1178–1185. doi:10.1002/2211-5463.12258
   PubMed Web of Science ®Google Scholar
• Milanesi S, Garibaldi S, Saio M, et al. Indoxyl sulfate induces renal fibroblast activation through a targetable heat shock protein 90-dependent pathway. Oxid Med Cell Longev. 2019;2019:2050183. doi:10.1155/2019/2050183
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Ise M, Seo H, Niwa T. Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int Suppl. 1997;62:S15–22.
   PubMedGoogle Scholar
• Chen CN, Chou CC, Tsai PSJ, Lee YJ. Plasma indoxyl sulfate concentration predicts progression of chronic kidney disease in dogs and cats. Vet J. 2018;232:33–39. doi:10.1016/j.tvjl.2017.12.011
   PubMed Web of Science ®Google Scholar
• Wu IW, Hsu KH, Lee CC, et al. P-cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant. 2011;26(3):938–947. doi:10.1093/ndt/gfq580
   PubMed Web of Science ®Google Scholar
• Kaesler N, Babler A, Floege J, Kramann R. Cardiac remodeling in chronic kidney disease. Toxins. 2020;12(3):161. doi:10.3390/toxins12030161
   PubMed Web of Science ®Google Scholar
• Nitta K, Iimuro S, Imai E, et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease. Clin Exp Nephrol. 2013;17(5):730–742. doi:10.1007/s10157-012-0758-4
   PubMed Web of Science ®Google Scholar
• London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12(12):2759–2767. doi:10.1681/ASN.V12122759
   PubMed Web of Science ®Google Scholar
• Sulemane S, Panoulas VF, Nihoyannopoulos P. Echocardiographic assessment in patients with chronic kidney disease: current update. Echocardiography. 2017;34(4):594–602. doi:10.1111/echo.13495
   PubMed Web of Science ®Google Scholar
• Pecoits-Filho R, Barberato SH. Echocardiography in chronic kidney disease: diagnostic and prognostic implications. Nephron Clin Pract. 2010;114(4):c242–7. doi:10.1159/000276575
   PubMedGoogle Scholar
• Amzulescu MS, De Craene M, Langet H, et al. Myocardial strain imaging: review of general principles, validation, and sources of discrepancies. Eur Heart J Cardiovasc Imaging. 2019;20(6):605–619. doi:10.1093/ehjci/jez041
   PubMed Web of Science ®Google Scholar
• Hung SC, Kuo KL, Wu CC, Tarng DC. Indoxyl sulfate: a novel cardiovascular risk factor in chronic kidney disease. J Am Heart Assoc. 2017;6:2. doi:10.1161/JAHA.116.005022
   Web of Science ®Google Scholar
• Krishnasamy R, Isbel NM, Hawley CM, et al. Left ventricular global longitudinal strain (GLS) is a superior predictor of all-cause and cardiovascular mortality when compared to ejection fraction in advanced chronic kidney disease. PLoS One. 2015;10(5):e0127044. doi:10.1371/journal.pone.0127044
   PubMed Web of Science ®Google Scholar
• Otani K, Higa Y, Kitano T, Nabeshima Y, Takeuchi M. Prediction of cardiac events using fully automated GLS and BNP titers in patients with known or suspected heart failure. PLoS One. 2020;15(6):e0234294. doi:10.1371/journal.pone.0234294
   PubMed Web of Science ®Google Scholar
• Park JJ, Park JB, Park JH, Cho GY. Global longitudinal strain to predict mortality in patients with acute heart failure. J Am Coll Cardiol. 2018;71(18):1947–1957. doi:10.1016/j.jacc.2018.02.064
   PubMed Web of Science ®Google Scholar
• Panoulas VF, Sulemane S, Konstantinou K, et al. Early detection of subclinical left ventricular myocardial dysfunction in patients with chronic kidney disease. Eur Heart J Cardiovasc Imaging. 2015;16(5):539–548. doi:10.1093/ehjci/jeu229
   PubMed Web of Science ®Google Scholar
• Sulemane S, Panoulas VF, Bratsas A, Grapsa J, Brown EA, Nihoyannopoulos P. Subclinical markers of cardiovascular disease predict adverse outcomes in chronic kidney disease patients with normal left ventricular ejection fraction. Int J Cardiovasc Imaging. 2017;33(5):687–698. doi:10.1007/s10554-016-1059-x
   PubMed Web of Science ®Google Scholar
• Shimazu S, Hirashiki A, Okumura T, et al. Association between indoxyl sulfate and cardiac dysfunction and prognosis in patients with dilated cardiomyopathy. Circ J. 2013;77(2):390–396. doi:10.1253/circj.CJ-12-0715
   PubMed Web of Science ®Google Scholar
• Fan PC, Chang JC, Lin CN, et al. Serum indoxyl sulfate predicts adverse cardiovascular events in patients with chronic kidney disease. J Formos Med Assoc. 2019;118(7):1099–1106. doi:10.1016/j.jfma.2019.03.005
   PubMed Web of Science ®Google Scholar